March 2013
MondayMorning;3/25/2013, Vol. 21 Issue 11, p1
The article offers information on the successful completion of the early-stage study of an oral-insulin NN1954 developed by the global healthcare company Novo Nordisk A/S. It mentions that Novo has completed the first of three phases of human testing by using Gastrointestinal Permeation Enhancement Technology (GIPET) of Merrion Pharmaceuticals PLC. It also informs that the clinical trials of the insulin are required for marketing approval.


Related Articles

  • Insulin Detemir Beats NPH at Blood Glucose Control. Trecroci, D. // Diabetes Health;Jul2004, Vol. 13 Issue 7, p14 

    Reports on the effectiveness of insulin detemir manufactured by Novo Nordisk on controlling blood glucose. Information on the clinical trial conducted to test the drug; Improvement in blood glucose among patients who received rapid-acting insulin; Risk of minor hypoglycemia in detemir-treated...

  • Obesity Drug Trial to Be Relaunched.  // Chain Drug Review;7/19/2010, Vol. 32 Issue 12, p54 

    The article reports that Novo Nordisk A/S has planned to re-launch of its late-stage clinical trial of obesity and diabetes drug liraglutide under the name Victoza.

  • Merrion Lands $58M Diabetes Deal with Novo Nordisk. Sheridan, Cormac // BioWorld International;1/21/2009, Vol. 14 Issue 3, p1 

    This article reports on a product development deal entered by Merrion Pharmaceuticals PLC with Novo Nordisk AS in 2009. Under the deal, Merrion is applying its Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology to a series of proprietary glucagon-like...

  • NovoLog (insulin aspart [rDNA origin] injection) Novo Nordisk.  // Clinician Reviews;Mar2007, Vol. 17 Issue 3, p52 

    The article evaluates the Novolog® insulin aspart injection from Novo Nordisk.

  • Novo says no to Lilly's insulin.  // Drug Topics;8/19/96, Vol. 140 Issue 16, p8 

    Details a letter issued by Novo Nordisk Pharmaceuticals to pharmacists recommending against the use of Eli Lilly manufactured Humulin insulin cartridges with NovoPen 1.5. Approval by Food & Drug Administration on use of NovoPen 1.5 with Novolin PenFill insulin cartridges.

  • Novo Nordisk Cancels Clinical Trials. Houlton, Sarah // Pharmaceutical Executive;Sep2002, Vol. 22 Issue 9, p28 

    Reports on Denmark-based Novo Nordisk's decision to suspend its clinical trials for the dual-acting insulin sensitizer, ragaglitazar. Adverse impact of the company's decision on its share price; Potential of ragaglitazar as a blood glucose regulator.

  • Pharma: Clinic Roundup.  // BioWorld Today;6/25/2012, Vol. 23 Issue 122, p8 

    The article reports that Denmark-based Novo Nordisk A/S announced that its ultra-long-lasting insulin degludec significantly reduced the rate of hypoglycemia at night in adults with Type II diabetes, compared with insulin glargin, based on data from its 52-week Phase IIIa trial.

  • Med-Tech Notes.  // Medical Device Daily;7/21/2010, Vol. 14 Issue 140, p2 

    The article reports that the 60,000th patient has been recruited by Novo Nordisk in the Alchieve study.

  • ZymoGenetics Licenses Anti-IL21 mAb.  // Bioworld Week;12/14/2009, Vol. 17 Issue 50, p3 

    The article reports on the rights of the preclinical anti-IL21 antibody granted by pharmaceutical firm ZymoGenetics Inc. in Seattle, Washington to its former parent company Novo Nordisk A/S. It is noted that a payment of 1.5 million dollars is required on the registration of the drug application...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics